Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2018 Feb 28

PMID 29484571

Citations 27

Authors

Mark Fleisher

Jan Marsal

Scott D Lee

Laura E Frado

Alyssa Parian

Burton I Korelitz

Brian G Feagan

Affiliations

Soon will be listed here.

Abstract

Background: Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action.

Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action.

Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy.

Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn's disease.

Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.

Citing Articles

Targeting alpha-4 integrin with natalizumab for intermediate uveitis associated with multiple sclerosis.

Calma A, Young S, Sandbach J, Riminton S, Reddel S, Ramanathan S Mult Scler J Exp Transl Clin. 2024; 10(4):20552173241301034.

PMID: 39660040 PMC: 11629426. DOI: 10.1177/20552173241301034.

Pyoderma Gangrenosum in an Ulcerative Colitis Patient on Vedolizumab.

Choe S, Bourgeois J, Nidamanuri S, Rubenzik R Cureus. 2024; 16(9):e69219.

PMID: 39398841 PMC: 11469654. DOI: 10.7759/cureus.69219.

Immune cell trafficking: a novel perspective on the gut-skin axis.

Zhang J, Yao Z Inflamm Regen. 2024; 44(1):21.

PMID: 38654394 PMC: 11040992. DOI: 10.1186/s41232-024-00334-5.

Choosing Therapy for Moderate to Severe Crohn's Disease.

Irani M, Abraham B J Can Assoc Gastroenterol. 2024; 7(1):1-8.

PMID: 38314180 PMC: 10836982. DOI: 10.1093/jcag/gwad023.

Role of Biologic Therapies in the Rheumatic Manifestations of Inflammatory Bowel Disease: A Systematic Analysis.

Nag A, Singh M, Thomas J, Ravichandran R, Gupta L, Panjiyar B Cureus. 2023; 15(9):e45195.

PMID: 37842480 PMC: 10576538. DOI: 10.7759/cureus.45195.

References

Harbord M, Annese V, Vavricka S, Allez M, Barreiro-de Acosta M, Boberg K . The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2015; 10(3):239-54. PMC: 4957476. DOI: 10.1093/ecco-jcc/jjv213. View

Peyrin-Biroulet L, Sandborn W, Sands B, Reinisch W, Bemelman W, Bryant R . Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015; 110(9):1324-38. DOI: 10.1038/ajg.2015.233. View

Principi M, Cassano N, Contaldo A, Iannone A, Losurdo G, Barone M . Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. World J Gastroenterol. 2016; 22(20):4802-11. PMC: 4873873. DOI: 10.3748/wjg.v22.i20.4802. View

Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, Sarzi-Puttini P . Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J Gastroenterol. 2009; 15(20):2469-71. PMC: 2686904. DOI: 10.3748/wjg.15.2469. View

Bernstein C, Blanchard J, Rawsthorne P, Yu N . The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001; 96(4):1116-22. DOI: 10.1111/j.1572-0241.2001.03756.x. View

Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View

Colombel J, Rutgeerts P, Sandborn W, Yang M, Camez A, Pollack P . Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013; 12(3):414-22.e5. DOI: 10.1016/j.cgh.2013.06.019. View

Stolwijk C, van Tubergen A, Castillo-Ortiz J, Boonen A . Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2013; 74(1):65-73. DOI: 10.1136/annrheumdis-2013-203582. View

Feagan B, Rubin D, Danese S, Vermeire S, Abhyankar B, Sankoh S . Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2016; 15(2):229-239.e5. DOI: 10.1016/j.cgh.2016.08.044. View

10.

Van Praet L, Jans L, Carron P, Jacques P, Glorieus E, Colman R . Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2013; 73(6):1186-9. DOI: 10.1136/annrheumdis-2013-203854. View

11.

Frolkis A, Dykeman J, Negron M, DeBruyn J, Jette N, Fiest K . Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013; 145(5):996-1006. DOI: 10.1053/j.gastro.2013.07.041. View

12.

Dulai P, Singh S, Casteele N, Boland B, Sandborn W . How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016; 22(4):998-1009. PMC: 5953904. DOI: 10.1097/MIB.0000000000000661. View

13.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

14.

Orchard T, Wordsworth B, Jewell D . Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998; 42(3):387-91. PMC: 1727027. DOI: 10.1136/gut.42.3.387. View

15.

Colombel J, Sands B, Rutgeerts P, Sandborn W, Danese S, DHaens G . The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016; 66(5):839-851. PMC: 5531223. DOI: 10.1136/gutjnl-2015-311079. View

16.

Bhagat S, Das K . A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994; 107(1):103-8. DOI: 10.1016/0016-5085(94)90066-3. View

17.

van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J . Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54(7):2136-46. DOI: 10.1002/art.21913. View

18.

Jaffe G, Dick A, Brezin A, Nguyen Q, Thorne J, Kestelyn P . Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016; 375(10):932-43. DOI: 10.1056/NEJMoa1509852. View

19.

Moss A . Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015; 3(1):63-8. PMC: 4324872. DOI: 10.1093/gastro/gou087. View

20.

Colombel J, Narula N, Peyrin-Biroulet L . Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology. 2016; 152(2):351-361.e5. DOI: 10.1053/j.gastro.2016.09.046. View